Transcription of E3 Implementation Working Group ICH E3 …
{{id}} {{{paragraph}}}
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Secretariat, Chemin Louis-Dunant 15, Box 195, 1211 Geneva 20, Switzerland Telephone: +41 (22) 338 32 06, Telefax: +41 (22) 338 32 30 E3 Implementation Working Group ICH E3 Guideline: Structure and Content of Clinical Study Reports Questions & Answers Current version dated 7 June 2012 In order to facilitate the Implementation of the E3 Guideline, the ICH Experts have developed a series of Q&As: E3 Q&As Document History Code History Date E3 Q&As Approval by the ICH Steering Committee under Step 4 7 June 2012 Reference ICH E3 Structure and Content of Clinical Study Reports November 1995 Last Update : 7 June 2012 E3 Q&As TABLE OF CONTENTS 1.
It should be noted that E3 was developed for submission of adequate and well-controlled clinical effectiveness studies. Nevertheless, the basic
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Q/A-LIST FOR THE SUBMISSION OF VARIATIONS, Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION, EU Module 1 eCTD Specification, Submission, ECTD Guidance Document, Q1A(R2) Guideline Stability Testing of New, Parallel assessment, Parallel assessment of Quality-by-Design, Flow chart for typical development